Treatment of acute myeloid leukemia in older patients

References

• Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J. Clin.56(2), 106–130 (2006).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia – new agents. Semin. Hematol.43(2), 96–106 (2006).
   PubMed Web of Science ®Google Scholar
• Mrozek K, Bloomfield CD. Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. In: The American Society of Hematology Education Program Book. American Society of Hematology, DC, USA 169–177 (2006).
   Google Scholar
• Leith CP, Kopecky KJ, Godwin J et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood89(9), 3323–3329 (1997).
   PubMed Web of Science ®Google Scholar
• Menzin J. Effects of initial treatment on survival among elderly AML patients: findings from the SEER–Medicare database. Blood108(11), A558 (2006).
   Google Scholar
• Larson R. Fifty years of clinical research by the Leukemia Committee of the Cancer and Leukemia Group B. Clin. Cancer Res.12(Suppl. 11), 3556–3563 (2006).
   Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized Phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol.7(9), 1268–1274 (1989).
   PubMed Web of Science ®Google Scholar
• Tilly H, Castaigne S, Bordessoule D et al. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer55(8), 1633–1636 (1985).
   PubMed Web of Science ®Google Scholar
• Roberts JD, Ershler WB, Tindle BH, Stewart JA. Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer56(5), 1001–1005 (1985).
   PubMedGoogle Scholar
• Degos L, Castaigne S, Tilly H, Sigaux F, Daniel MT. Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin. Oncol.12(2 Suppl. 3), 196–199 (1985).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J. Clin. Oncol.4(12), 1857–1864 (1986).
   PubMed Web of Science ®Google Scholar
• Burnett A. Low-dose ara-C with or without retinoid in older patients not considered fit for intensive chemotherapy. Blood104, A249 (2004).
   Google Scholar
• Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch. Intern. Med.162(14), 1597–1603 (2002).
   PubMed Web of Science ®Google Scholar
• Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med.341(27), 2061–2067 (1999).
   PubMed Web of Science ®Google Scholar
• Estey EH. General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia. Semin. Hematol.43(2), 89–95 (2006).
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood98(5), 1312–1320 (2001).
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P, Beran M et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood90(8), 2969–2977 (1997).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Cortes J et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer106(5), 1090–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Baudard M, Beauchamp-Nicoud A, Delmer A et al. Has the prognosis of adult patients with acute myeloid leukemia improved over years? A single institution experience of 784 consecutive patients over a 16-year period. Leukemia13(10), 1481–1490 (1999).
   PubMed Web of Science ®Google Scholar
• Johnson PR, Yin JA. Prognostic factors in elderly patients with acute myeloid leukaemia. Leuk. Lymphoma16(1–2), 51–56 (1994).
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood108(10), 3280–3288 (2006).
   PubMed Web of Science ®Google Scholar
• Gupta V, Chun K, Yi QL et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer103(10), 2082–2090 (2005).
   PubMed Web of Science ®Google Scholar
• Marcucci G, Mrozek K, Ruppert AS et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J. Clin. Oncol.23(24), 5705–5717 (2005).
   PubMed Web of Science ®Google Scholar
• Schoch C, Kern W, Schnittger S et al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica89(9), 1082–1090 (2004).
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR et al. Age and acute myeloid leukemia. Blood107(9), 3481–3485 (2006).
   PubMed Web of Science ®Google Scholar
• Giles FJ, Borthakur G, Ravandi F et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br. J. Haematol. (2007) (Epub ahead of print).
   Google Scholar
• Sorror ML, Maris MB, Storb R et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood106(8), 2912–2919 (2005).
   PubMed Web of Science ®Google Scholar
• List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood98(12), 3212–3220 (2001).
   PubMed Web of Science ®Google Scholar
• van der Holt B, Lowenberg B, Burnett AK et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood106(8), 2646–2654 (2005).
   PubMed Web of Science ®Google Scholar
• Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B study 9720. Blood100(4), 1224–1232 (2002).
   PubMed Web of Science ®Google Scholar
• Cripe LD, Li X, Litzow M et al. A randomized, placebo-controlled, double blind trial of the MDR modulator, zosuquidar, during conventional induction and post-remission therapy for pts > 60 years of age with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS): ECOG 3999. Blood108, A129 (2006).
   Web of Science ®Google Scholar
• Larson RA, Boogaerts M, Estey E et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia16(9), 1627–1636 (2002).
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol.19(13), 3244–3254 (2001).
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Knovich MA, Bayer RL et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk. Lymphoma43(10), 1951–1955 (2002).
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Giles FJ et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood99(12), 4343–4349 (2002).
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Stasi R et al. Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a Phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leukemia19(10), 1768–1773 (2005).
   PubMed Web of Science ®Google Scholar
• Kell WJ, Burnett AK, Chopra R et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood102(13), 4277–4283 (2003).
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Ritchie EK, Schuster MW et al. Gemtuzumab ozogamicin is an acceptable alternative to anthracyclines in combination with standard dose infusional cytarabine as induction therapy for elderly patients with acute myeloid leukemia (AML). Blood106, A221 (2005).
   Google Scholar
• Lancet JE, Karp JE. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood102(12), 3880–3889 (2003).
   PubMed Web of Science ®Google Scholar
• Lancet JE, Gojo I, Gotlib J et al. A Phase II study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood109(4), 1387–1394 (2007).
   PubMed Web of Science ®Google Scholar
• Small D. FLT3 mutations: biology and treatment. In: The American Society of Hematology Education Program Book. American Society of Hematology, DC, USA 178–184 (2006).
   Google Scholar
• Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia14(4), 675–683 (2000).
   PubMed Web of Science ®Google Scholar
• Smith BD, Levis M, Beran M et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood103(10), 3669–3676 (2004).
   PubMed Web of Science ®Google Scholar
• Stone RM, DeAngelo DJ, Klimek V et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood105(1), 54–60 (2005).
   PubMed Web of Science ®Google Scholar
• Fiedler W, Serve H, Dohner H et al. A Phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood105(3), 986–993 (2005).
   PubMed Web of Science ®Google Scholar
• Knapper S, Mills KI, Gilkes AF et al. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood108(10), 3494–3503 (2006).
   PubMed Web of Science ®Google Scholar
• Knapper S, Burnett AK, Littlewood T et al. A Phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood108(10), 3262–3270 (2006).
   PubMed Web of Science ®Google Scholar
• Giles F, Thomas D, Garcia-Manero G et al. A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin. Cancer Res.10(9), 2908–2917 (2004).
   PubMed Web of Science ®Google Scholar
• Giles F, Verstovsek S, Faderl S et al. A Phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk. Res.30(12), 1591–1595 (2006).
   PubMed Web of Science ®Google Scholar
• Vey N, Giles F. Cloretazine for the treatment of acute myeloid leukemia. Exp. Rev. Anticancer Ther.6(3), 321–328 (2006).
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Tse W, Khan KD et al. A Phase I study of Cloretazine® and temozolomide in patients with hematologic malignancies. Blood108, A557 (2006).
   Google Scholar
• Giles F, Rizzieri D, Karp J et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J. Clin. Oncol.25(1), 25–31 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Gandhi V, Cortes J et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood102(7), 2379–2386 (2003).
   PubMed Web of Science ®Google Scholar
• Burnett AK, Baccarani M, Johnson P et al. A Phase II study (Biov-121) of clofarabine monotherapy first line in patients aged 65 years or older with acute myeloid leukemia for whom standard intensive chemotherapy is not considered suitable. BloodA130 (2006).
   Google Scholar
• Faderl S, Verstovsek S, Cortes J et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood108(1), 45–51 (2006).
   PubMed Web of Science ®Google Scholar
• Faderl S, Ravandi F, Ferrajoli A et al. Clofarabine and clofarabine plus low-dose cytarabine (ara-C) as induction therapy for patients (pts) ≥ 60 years with newly diagnosed acute myeloid leukemia (AML). Blood106, A786 (2005).
   Google Scholar
• Vey N, Bosly A, Guerci A et al. Arsenic trioxide in patients with myelodysplastic syndromes: a Phase II multicenter study. J. Clin. Oncol.24(16), 2465–2471 (2006).
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Slack J, Hainsworth JD et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J. Clin. Oncol.24(16), 2456–2464 (2006).
   PubMed Web of Science ®Google Scholar
• Parmar S, Rundhaugen LM, Boehlke L et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk. Res.28(9), 909–919 (2004).
   PubMed Web of Science ®Google Scholar
• Douer D, Watkins K, Louie R et al. Treatment of non-APL acute myelogenous leukemia with intravenous arsenic trioxide plus ascorbic acid. Blood108, A554 (2006).
   Google Scholar
• Roboz GJ, Ritchie EK, Allen-Bard S et al. Arsenic trioxide (ATO) is safe and effective in combination with low-dose Ara-C (LDAC) for the treatment of IPSS-2 myelodysplastic syndrome (MDS) and poor-prognosis acute myeloid leukemia (AML) in elderly patients. Blood106, A528 (2005).
   Google Scholar
• de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin. Hematol.43(2), 107–117 (2006).
   PubMed Web of Science ®Google Scholar
• Wong R, Giralt SA, Martin T et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. Blood102(8), 3052–3059 (2003).
   PubMedGoogle Scholar
• Shimoni A, Kroger N, Zabelina T et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning. Leukemia19(1), 7–12 (2005).
   PubMed Web of Science ®Google Scholar
• Hegenbart U, Niederwieser D, Sandmaier BM et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J. Clin. Oncol.24(3), 444–453 (2006).
   PubMed Web of Science ®Google Scholar
• Kroger N, Shimoni A, Zabelina T et al. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant.37(4), 339–344 (2006).
   PubMed Web of Science ®Google Scholar
• van Besien K, Artz A, Smith S et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J. Clin. Oncol.23(24), 5728–5738 (2005).
   PubMed Web of Science ®Google Scholar
• Estey E, de Lima M, Tibes R et al. Prospective feasibility analysis of reduced intensity conditioning regimens (RIC) for hematopoetic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood109(4), 1395–1400 (2007)
   PubMed Web of Science ®Google Scholar
• Platzbecker U, Thiede C, Fussel M et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia20(4), 707–714 (2006).
   PubMed Web of Science ®Google Scholar
• Estey EH, Garcia-Manero G, Giles F, Kantarjian HM. Effect of failure to respond to targeted therapy on response to cytotoxic therapy in pts age ≥ 60 with newly-diagnosed AML. BloodA556 (2006).
   Google Scholar
• Estey EH, Bedikian SH, Witter DC, Pierce SA, Giles FJ. The predictive value of a “positive” ASH abstract in AML therapeutics. BloodA555 (2006).
   Google Scholar
• Estey E. Clinical trials in AML of the elderly: should we change our methodology? Leukemia18(11), 1772–1774 (2004).
   PubMedGoogle Scholar
• Mayer RJ, Davis RB, Schiffer CA et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N. Engl. J. Med.331(14), 896–903 (1994).
   PubMed Web of Science ®Google Scholar
• Stone R. Granulocyte–macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N. Engl. J. Med.332, 1671–1677 (1995).
   PubMed Web of Science ®Google Scholar
• Rowe JM, Andersen JW, Mazza JJ et al. A randomized placebo-controlled Phase III study of granulocyte–macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood86(2), 457–462 (1995).
   PubMed Web of Science ®Google Scholar
• Godwin JE, Kopecky KJ, Head DR et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study (9031). Blood91(10), 3607–3615 (1998).
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy – the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch–Belgian Hemato-Oncology Cooperative HOVON Group. J. Clin. Oncol.16(3), 872–881 (1998).
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood98(5), 1302–1311 (2001).
   PubMed Web of Science ®Google Scholar
• Anderson JE, Kopecky KJ, Willman CL et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood100(12), 3869–3876 (2002).
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Berdel WE et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD–HAM–TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J. Clin. Oncol.21(24), 4496–4504 (2003).
   PubMed Web of Science ®Google Scholar
• Rowe JM, Neuberg D, Friedenberg W et al. A Phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood103(2), 479–485 (2004).
   PubMed Web of Science ®Google Scholar